At-Home Drug of Abuse (DOA) Testing Market - 2024-2033

May 2025 | 207 pages | ID: A398204AE4E6EN
DataM Intelligence

Abstracts

The At-Home Drug of Abuse (DOA) Testing Market was valued at US$ 2.62 Billion in 2024 and is anticipated to reach US$ 5.09 Billion by 2033, at a CAGR of 0.077 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the At-Home Drug of Abuse (DOA) Testing Market.

This report delivers a comprehensive overview of the At-Home Drug of Abuse (DOA) Testing Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding At-Home Drug of Abuse (DOA) Testing Market. The At-Home Drug of Abuse (DOA) Testing Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

At-Home Drug of Abuse (DOA) Testing Market Scope:

Key Players

• Abbott Laboratories

Major Highlights

This report delivers a comprehensive overview of the At-Home Drug of Abuse (DOA) Testing Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding At-Home Drug of Abuse (DOA) Testing Market. The At-Home Drug of Abuse (DOA) Testing Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS

3.1. Key Trends and Future Projections

4. SNIPPET BY PRODUCT

4.1. Snippet by Drug Type
4.2. Snippet by End User
4.3. Snippet by Region

5. DYNAMICS

5.1. Impacting Factors
  5.1.1. Drivers
    5.1.1.1. Rising Substance Abuse Rates and Early Detection Needs
    5.1.1.2. Advancements in Testing Technologies
    5.1.1.3. Increasing Awareness of Mental Health and Substance Abuse
  5.1.2. Restraints
    5.1.2.1. Concerns Over Test Accuracy and Interpretation
    5.1.2.2. Regulatory Challenges
    5.1.2.3. Risk of Unsupervised Interpretation
  5.1.3. Opportunity
    5.1.3.1. Emergence of Multi-Panel and Saliva-Based Tests
    5.1.3.2. Expansion into Emerging Markets
  5.1.4. Impact Analysis

6. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

6.1. Market Leaders and Pioneers
  6.1.1. Emerging Pioneers and Prominent Players
  6.1.2. Established leaders with largest largest-selling Brand
  6.1.3. Market leaders with established products & Services
6.2. CXO Perspectives
6.3. Latest Developments and Breakthroughs
6.4. Case Studies/Ongoing Research
6.5. Regulatory and Reimbursement Landscape
  6.5.1. North America
  6.5.2. Europe
  6.5.3. Asia Pacific
  6.5.4. South America
  6.5.5. Middle East & Africa
6.6. Porter’s Five Force Analysis
6.7. Supply Chain Analysis
6.8. Patent Analysis
6.9. SWOT Analysis
6.10. Unmet Needs and Gaps
6.11. Recommended Strategies for Market Entry and Expansion
6.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
6.13. Pricing Analysis and Price Dynamics
6.14. Key Opinion Leaders

7. GLOBAL AT-HOME DRUG OF ABUSE (DOA) TESTING MARKET, BY PRODUCT

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  7.1.2. Market Attractiveness Index, By Product
7.2. Urine Drug Test Kits*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Oral Fluid Drug Test Kits
7.4. Hair Drug Test Kits
7.5. Saliva Drug Test Kits
7.6. Others

8. GLOBAL AT-HOME DRUG OF ABUSE (DOA) TESTING MARKET, BY DRUG TYPE

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  8.1.2. Market Attractiveness Index, By Drug Type
8.2. Marijuana (THC)*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cocaine
8.4. Amphetamines
8.5. Opiates
8.6. Benzodiazepines
8.7. Methamphetamines
8.8. Others

9. GLOBAL AT-HOME DRUG OF ABUSE (DOA) TESTING MARKET, BY END USER

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Diagnostic Centers
9.4. Clinical Laboratories
9.5. Homecare Settings

10. GLOBAL AT-HOME DRUG OF ABUSE (DOA) TESTING MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

11. INTRODUCTION

11.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  11.1.1. Market Attractiveness Index, By Region
11.2. North America
  11.2.1. Introduction
  11.2.2. Key Region-Specific Dynamics
  11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.2.6.1. U.S.
    11.2.6.2. Canada
    11.2.6.3. Mexico
11.3. Europe
  11.3.1. Introduction
  11.3.2. Key Region-Specific Dynamics
  11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.3.6.1. Germany
    11.3.6.2. U.K.
    11.3.6.3. France
    11.3.6.4. Spain
    11.3.6.5. Italy
    11.3.6.6. Rest of Europe
11.4. South America
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.4.6.1. Brazil
    11.4.6.2. Argentina
    11.4.6.3. Rest of South America
11.5. Asia-Pacific
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.5.6.1. China
    11.5.6.2. India
    11.5.6.3. Japan
    11.5.6.4. South Korea
    11.5.6.5. Rest of Asia-Pacific
11.6. Middle East and Africa
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

13. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS

13.1. Market Share Analysis and Positioning Matrix
13.2. Strategic Partnerships, Mergers & Acquisitions
13.3. Key Developments in Product Portfolios and Innovations
13.4. Company Benchmarking

14. COMPANY PROFILES

14.1. Abbott Laboratories*
  14.1.1. Company Overview
  14.1.2. Product Portfolio
    14.1.2.1. Product Description
    14.1.2.2. Product Key Performance Indicators (KPIs)
    14.1.2.3. Historic and Forecasted Product Sales
    14.1.2.4. Product Sales Volume

15. FINANCIAL OVERVIEW

15.1. Company Revenue
  15.1.1. Geographical Revenue Shares
    15.1.1.1. Revenue Forecasts
  15.1.2. Key Developments
    15.1.2.1. Mergers & Acquisitions
    15.1.2.2. Key Product Development Activities
    15.1.2.3. Regulatory Approvals, etc.
  15.1.3. SWOT Analysis
15.2. OraSure Technologies, Inc
15.3. Psychemedics Corporation
15.4. NMS Labs
15.5. Premier Biotech
15.6. First Check Diagnostics
15.7. Atlas Medical
15.8. Cliawaived, Inc
15.9. Frenovo Biotech (*LIST NOT EXHAUSTIVE)

16. ASSUMPTIONS AND RESEARCH METHODOLOGY

16.1. Data Collection Methods
16.2. Data Triangulation
16.3. Forecasting Techniques
16.4. Data Verification and Validation

17. APPENDIX

17.1. About Us and Services
17.2. Contact Us